Stronger Life Science Patents (MichBio)

Aurora Consulting
Aurora ConsultingAurora Consulting
Stronger
Life Science Patents
This presentation is for information purposes only and does not
constitute legal advice.
ASHLEY SLOAT, Ph.D. | September 18, 2023
Ashley Sloat, Ph.D.
President & Director of Patent Strategy
an illogical, unpredictable, chaotic mess...
“
– Federal Circuit Chief Judge Paul Michel (retired)
made it difficult for inventors, businesses, and
other patent stakeholders to reliably and
predictably determine what subject matter is
patent eligible
“
– Elizabeth Prelogar, U.S. Solicitor General
innovation cannot thrive in uncertainty
“
– Kathi Vidal, USPTO Director and Under Secretary of Commerce
80%
innovation does not include patentable subject matter
Innovation doesn’t wait.
Let us be clear: investments in the biotech
industry are based entirely on patents. Without
strong patents, we cannot raise money to find
cures for disease.
“
– Hans Bishop, Founder at Altos Labs & former Head of Juno Therapeutics
Stronger Life Science Patents (MichBio)
Overview: Stronger Life Science Patents
•Eligibility and enablement
•State of the law
•Funding sources and regulatory delays
•Practical tips
•Recent legislative movements
There are seven
days in the week
and SOMEDAY isn’t
one of them.
“
Rejection & Invalidation Gates
• Section 101 – patent ineligibility or lack of utility
• Section 102 – lack of novelty
• Section 103 – the claimed invention is obvious and/or
• Section 112 – lack of adequate description
Eligibility.
What subject matters are eligible for patent protection?
Enablement.
The fundamental deal of the patent system.
Eligibility: Patentable Subject Matter
“Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof,
may obtain a patent therefor, subject to the conditions
and requirements of this title.”
35 U.S.C. § 101
Eligibility: Judicial Exceptions
• Laws of nature
• Natural phenomena
• Abstract ideas
Eligibility: Judicial Exceptions
• scientific principles
• naturally occurring phenomena
• mental processes
• mathematical algorithms
Practical application of
natural phenomenon
Life Science Challenge:
The Reality of
Past 5 Years
1631 Art Unit
Molecular Bio,
Bioinformatics, Nucleic
Acids, Recombinant
DNA/RNA, Gene
Regulation
Mayo Collaborative Services v.
Prometheus Laboratories, Inc.
Unpatentable natural laws transformed into patent-eligible
applications of those laws?
Statutory
Category?
YES Judicial
Exception?
Practical
Application?
YES Significantly
More?
NO
YES
NO
YES
Eligible
NO
Subject Matter Eligibility Guidance
Process
machine
manufacture
composition of matter
Laws of nature
Natural phenomena
Abstract ideas
Not Eligible
NO
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
A significant, but unpatentable, contribution to the medical field.
The solution lies in the intent
“…in applying the §101 exception, we must distinguish
between patents that claim the building blocks of
human ingenuity and those that integrate the
building blocks into something more, thereby
transforming them into a patent-eligible invention”
Alice Corp. v. CLS Bank Int’l SCOTUS opinion
The solution lies in the intent
“At some level, all inventions embody, use, reflect, rest upon,
or apply laws of nature, natural phenomena, or abstract
ideas. Thus, an invention is not rendered ineligible for patent
simply because it involves an abstract concept. Applications
of such concepts to a new and useful end … remain eligible
for patent protection.”
Alice Corp. v. CLS Bank Int’l SCOTUS opinion
Key Tips for Derisking Eligibility
• Practical applications.
• Improvement over prior art methods.
• Overcome a particular technical challenge.
• Different claim types.
Building blocks into something more
"Unless you puke, faint or die, keep going!"
– Jillian Michaels
Enablement.
The fundamental deal of the patent system.
Enablement: Adequate Description
“The specification shall contain a written description of
the invention, and of the manner and process of
making and using it, in such full, clear, concise, and
exact terms as to enable any person skilled in the art
… to make and use the same…”
35 U.S.C. § 112
Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
101
Patentable
Subject Matter
102
Novelty
103
Obviousness
112a
Written
Description
112b
Enablement
All
Rejection
Bases
Top Art Unit
Groups
for 112
Rejections
Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
Higher disclosure bar for
unpredictable arts
Life Science Challenge:
Enabling Unpredictable Arts
“the scope of enablement … varies inversely with
the degree of unpredictability of the factors involved”
Application of Joseph D. Fisher, 427 F.2d 833 (C.C.P.A. 1970)
Enablement
Mechanical arts
Physics
Chemical arts
Life Sciences
Predictability
Digital Health
The Enablement Test
“…as to enable any person skilled in the art … to make
and use the … invention.”
35 U.S.C. § 112
“…without undue experimentation”.
Minerals Separation Ltd. v. Hyde
... coupled with information known in the art ...”.
United States v. Telectronics, Inc
Genus Claim: covers a group of related
chemicals
Species Claim: covers a single compound or
narrow slice of compounds possibly without
coverage of analogs, derivatives, or
compounds in the same family
…the law has changed dramatically in the last thirty
years, to the point where it is nearly impossible to
maintain a valid genus claim. Courts almost always
hold them invalid, either at trial or on appeal.
“
Harvard Journal of Law & Technology: Death of the Genus Claim
USPTO Genus Misinformation
Disputed by Third Parties
Community reports have identified this guidance as violating the
Community Policy on Harmfully Misleading Information
United States Patent and Trademark Office
MPEP
III. WORKING EXAMPLES AND A CLAIMED GENUS
For a claimed genus, representative examples together with a statement applicable to
the genus as a whole will ordinarily be sufficient if one skilled in the art …would expect
the claimed genus could be used in that manner without undue experimentation.
Proof of enablement will be required for other members of the claimed genus only
where adequate reasons are advanced by the examiner to establish that a person
skilled in the art could not use the genus as a whole without undue experimentation.
Examples of the Genus Claim Deaths
• A nascent, unpredictable field rife with failure
can cause enablement issues
–Enzo Biochem v. Calgene (Fed. Circ. 1999)
–Claimed antisense DNA technology
• Iterative trial-and-error lead by spec can
create enablement issue
–Wyeth v. Abbott (Fed. Circ. 2010)
–Rapamycin chemicals for treatment of
restenosis
Death of the Genus Claim
• Undue Experimentation despite described
screening process allowing for straightforward ID
of working embodiments
– Idenix Pharma v. Gilead (Fed. Circ. 2019)
– 2-methyl nucleoside for treatment of HCV
• Not Enabled despite antibody science being well-
known, guidance provided, working examples,
identified specific amino acids for binding
– Amgen v. Sanofi (Supreme Court 2023)
The solution lies in the intent
A bargain between the inventor and society.
Wands Factors
1. Quantity of experimentation necessary
2. Amount of direction or guidance presented
3. Presence or absence of working examples
4. Nature of the invention
5. State of the prior art
6. Relative skill of those in the art
7. Predictability or unpredictability of the art
8. Breadth of the claims
In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
Key Tips for Derisking Enablement
• Provide ample direction and specificity.
• Build breadth through examples.
• Reinforce genus with species.
• Consider a narrower claim backstop.
• Disclose experimentation tips.
• File continuation applications.
• Consider alternative strategies.
Funding Sources and
Regulatory Delays
Life Science Challenges:
Gov’t grants
come with
strings
attached…
SBIR / STTR
Government Grant Gotchyas
1. Actually reduce invention to practice before using money –
otherwise Gov’t has a nonexclusive, nontransferrable,
irrevocable, paid-up license to practice the invention
throughout the world
• Even if your patent was filed before the grant….
2. If subject invention is unelected at 2 years, then gov’t
receives title of invention.
3. If hire subcontractor to perform some of the work, any subject
invention from the subcontractor cannot be assigned to your
company – subcontractor retains ownership.
Stronger Life Science Patents (MichBio)
Maximize Your Exclusivity Window
1. Patent Term Extension
2. New Drug Product Exclusivity
3. New Clinical Investigation Exclusivity
“trainers who say ‘last one’ are the
reason I have trust issues"
Reform on the horizon?
Current events and legislative solutions.
Patent Eligibility Restoration Act of 2023
• Would amend the U.S. Patent Act to clarify the
application of 35 U.S.C. Section 101 and address
uncertainty plaguing software and biotechnology
inventions
• Effectively overruling Alice and previous SCOTUS cases
such as Mayo
• Wide bipartisan and community support
Stronger Life Science Patents (MichBio)
Stronger Life
Science Patent
Resources
• This slide deck
• Blog posts on timelines and exclusivity
• Podcasts on enablement and gov’t grants
Questions or Comments?
Contact us!
ashley@aurorapatents.com
(231) 715-1001
aurorapatents.com
@AuroraPatents
Podcast @ patentlystrategic.buzzsprout.com
1 de 52

Recomendados

2017 01-25 uwls-apl_biotech 112 por
2017 01-25 uwls-apl_biotech 1122017 01-25 uwls-apl_biotech 112
2017 01-25 uwls-apl_biotech 112Gary M. Myles, Ph.D.
239 vistas59 diapositivas
The Case Of Incyte Genomics por
The Case Of Incyte GenomicsThe Case Of Incyte Genomics
The Case Of Incyte Genomicsjrstorella
1.2K vistas21 diapositivas
Enforcement and Patentable Subject Matter: The U.S. Dilemma por
Enforcement and Patentable Subject Matter: The U.S. DilemmaEnforcement and Patentable Subject Matter: The U.S. Dilemma
Enforcement and Patentable Subject Matter: The U.S. DilemmaPatterson Thuente IP
50 vistas31 diapositivas
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne... por
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...Stephen Cranwell
444 vistas6 diapositivas
Biotechnology Novelty And Nonobviousness 14 Sep10 por
Biotechnology Novelty And Nonobviousness 14 Sep10Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10Gary M. Myles, Ph.D.
274 vistas52 diapositivas
Gene Patenting Life By Michael Crichton Summary por
Gene Patenting Life By Michael Crichton SummaryGene Patenting Life By Michael Crichton Summary
Gene Patenting Life By Michael Crichton SummarySue Jones
2 vistas42 diapositivas

Más contenido relacionado

Similar a Stronger Life Science Patents (MichBio)

THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES por
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESTHE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESSaravanan A
807 vistas27 diapositivas
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 por
2020 01-28 uwls-apl_biotech_disclosure under 35_usc1122020 01-28 uwls-apl_biotech_disclosure under 35_usc112
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112Gary M. Myles, Ph.D.
61 vistas45 diapositivas
11 Biotechnology Patents_Subject Matter Exclusions.pptx por
11 Biotechnology Patents_Subject Matter Exclusions.pptx11 Biotechnology Patents_Subject Matter Exclusions.pptx
11 Biotechnology Patents_Subject Matter Exclusions.pptxssuserdf29f0
29 vistas28 diapositivas
Patent Year In Review 2011 60 Minutes Slides por
Patent Year In Review 2011 60 Minutes SlidesPatent Year In Review 2011 60 Minutes Slides
Patent Year In Review 2011 60 Minutes Slidesemanzo7672
468 vistas79 diapositivas
Biotechnology Patent Eligibility por
Biotechnology Patent EligibilityBiotechnology Patent Eligibility
Biotechnology Patent EligibilityGary M. Myles, Ph.D.
895 vistas97 diapositivas
Gene patenting por
Gene patentingGene patenting
Gene patentingHina Zamir Noori
5.3K vistas5 diapositivas

Similar a Stronger Life Science Patents (MichBio)(20)

THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES por Saravanan A
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESTHE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
Saravanan A807 vistas
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 por Gary M. Myles, Ph.D.
2020 01-28 uwls-apl_biotech_disclosure under 35_usc1122020 01-28 uwls-apl_biotech_disclosure under 35_usc112
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
11 Biotechnology Patents_Subject Matter Exclusions.pptx por ssuserdf29f0
11 Biotechnology Patents_Subject Matter Exclusions.pptx11 Biotechnology Patents_Subject Matter Exclusions.pptx
11 Biotechnology Patents_Subject Matter Exclusions.pptx
ssuserdf29f029 vistas
Patent Year In Review 2011 60 Minutes Slides por emanzo7672
Patent Year In Review 2011 60 Minutes SlidesPatent Year In Review 2011 60 Minutes Slides
Patent Year In Review 2011 60 Minutes Slides
emanzo7672468 vistas
Predictable Results from Unpredictable Arts por Aurora Consulting
Predictable Results from Unpredictable ArtsPredictable Results from Unpredictable Arts
Predictable Results from Unpredictable Arts
Aurora Consulting467 vistas
Patents and intellectual property por Janet Stemwedel
Patents and intellectual propertyPatents and intellectual property
Patents and intellectual property
Janet Stemwedel657 vistas
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005 por SterneKessler
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SterneKessler320 vistas
Biotech Patentable Subject Matter After Bilski por wardjohn1346
Biotech Patentable Subject Matter After BilskiBiotech Patentable Subject Matter After Bilski
Biotech Patentable Subject Matter After Bilski
wardjohn1346597 vistas
Non patentable inventions in india por atuljaybhaye
Non patentable inventions in indiaNon patentable inventions in india
Non patentable inventions in india
atuljaybhaye1.3K vistas
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et... por Lawrence Kass
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...
Lawrence Kass186 vistas
016 patent infringement por 456 986
016 patent infringement016 patent infringement
016 patent infringement
456 9862.3K vistas
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth... por Kirby Drake
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Kirby Drake49 vistas
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t... por Patterson Thuente IP
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...

Más de Aurora Consulting

Patent Claims por
Patent ClaimsPatent Claims
Patent ClaimsAurora Consulting
164 vistas23 diapositivas
Protect Before You Pitch (MichBio) por
Protect Before You Pitch (MichBio)Protect Before You Pitch (MichBio)
Protect Before You Pitch (MichBio)Aurora Consulting
42 vistas10 diapositivas
Government Grants and Patent Rights por
Government Grants and Patent RightsGovernment Grants and Patent Rights
Government Grants and Patent RightsAurora Consulting
233 vistas18 diapositivas
Open Source and Patent Rights: Collaboration with Consequences por
Open Source and Patent Rights: Collaboration with ConsequencesOpen Source and Patent Rights: Collaboration with Consequences
Open Source and Patent Rights: Collaboration with ConsequencesAurora Consulting
392 vistas18 diapositivas
Amgen V. Sanofi.pdf por
Amgen V. Sanofi.pdfAmgen V. Sanofi.pdf
Amgen V. Sanofi.pdfAurora Consulting
625 vistas29 diapositivas
Foreign Filing Licenses por
Foreign Filing LicensesForeign Filing Licenses
Foreign Filing LicensesAurora Consulting
469 vistas16 diapositivas

Más de Aurora Consulting(20)

Open Source and Patent Rights: Collaboration with Consequences por Aurora Consulting
Open Source and Patent Rights: Collaboration with ConsequencesOpen Source and Patent Rights: Collaboration with Consequences
Open Source and Patent Rights: Collaboration with Consequences
Aurora Consulting392 vistas
Into the Patentverse Vol. 2: AR, VR, and Virtual Infringement por Aurora Consulting
Into the Patentverse Vol. 2: AR, VR, and Virtual InfringementInto the Patentverse Vol. 2: AR, VR, and Virtual Infringement
Into the Patentverse Vol. 2: AR, VR, and Virtual Infringement
Aurora Consulting468 vistas
Mean Plus Function: : The Risk of Losing Your Way por Aurora Consulting
Mean Plus Function: : The Risk of Losing Your WayMean Plus Function: : The Risk of Losing Your Way
Mean Plus Function: : The Risk of Losing Your Way
Aurora Consulting538 vistas
American Axle: 101 Rejections of Mechanical Claims por Aurora Consulting
American Axle: 101 Rejections of Mechanical ClaimsAmerican Axle: 101 Rejections of Mechanical Claims
American Axle: 101 Rejections of Mechanical Claims
Aurora Consulting529 vistas
Prenuptial Patenting: Responsible Engagement with Engineering Firms por Aurora Consulting
Prenuptial Patenting: Responsible Engagement with Engineering FirmsPrenuptial Patenting: Responsible Engagement with Engineering Firms
Prenuptial Patenting: Responsible Engagement with Engineering Firms
Aurora Consulting433 vistas
Fortifying Life Science Patents: Eligibility and Enablement por Aurora Consulting
Fortifying Life Science Patents: Eligibility and EnablementFortifying Life Science Patents: Eligibility and Enablement
Fortifying Life Science Patents: Eligibility and Enablement
Aurora Consulting439 vistas
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTs por Aurora Consulting
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTsWeb 3 and IP: Cryptocurrencies, Blockchain, and NFTs
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTs
Aurora Consulting507 vistas
Inventorship: Who should be listed as an inventor for a patent? por Aurora Consulting
Inventorship: Who should be listed as an inventor for a patent?Inventorship: Who should be listed as an inventor for a patent?
Inventorship: Who should be listed as an inventor for a patent?
Aurora Consulting552 vistas
Decrypting Software Patents: Key Insights for IP Success por Aurora Consulting
Decrypting Software Patents: Key Insights for IP SuccessDecrypting Software Patents: Key Insights for IP Success
Decrypting Software Patents: Key Insights for IP Success
Aurora Consulting676 vistas
Patent Searching: Sleuthing Your Way to Stronger Patents por Aurora Consulting
Patent Searching: Sleuthing Your Way to Stronger PatentsPatent Searching: Sleuthing Your Way to Stronger Patents
Patent Searching: Sleuthing Your Way to Stronger Patents
Aurora Consulting663 vistas
Global & U.S. Patents for Digital Health Startups por Aurora Consulting
Global & U.S. Patents for Digital Health StartupsGlobal & U.S. Patents for Digital Health Startups
Global & U.S. Patents for Digital Health Startups
Aurora Consulting55 vistas
Google v Oracle: The Future of Software and Fair Use por Aurora Consulting
Google v Oracle: The Future of Software and Fair UseGoogle v Oracle: The Future of Software and Fair Use
Google v Oracle: The Future of Software and Fair Use
Aurora Consulting722 vistas

Último

Obesity.pdf por
Obesity.pdfObesity.pdf
Obesity.pdfRutvikunvar Raualji (PT)
112 vistas30 diapositivas
The Art of naming drugs.pptx por
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptxDanaKarem1
13 vistas48 diapositivas
TQM ASSIGMENT 3.pdf por
TQM ASSIGMENT 3.pdfTQM ASSIGMENT 3.pdf
TQM ASSIGMENT 3.pdfد حاتم البيطار
11 vistas11 diapositivas
MENSTRUAL CYCLE.pdf por
MENSTRUAL CYCLE.pdfMENSTRUAL CYCLE.pdf
MENSTRUAL CYCLE.pdfRutvikunvar Raualji (PT)
18 vistas24 diapositivas
Examining Pleural Fluid.pptx por
Examining Pleural Fluid.pptxExamining Pleural Fluid.pptx
Examining Pleural Fluid.pptxFareeha Riaz
19 vistas18 diapositivas
3rd lecture PCR-Presentation.ppt por
3rd lecture PCR-Presentation.ppt3rd lecture PCR-Presentation.ppt
3rd lecture PCR-Presentation.pptgayubshah
6 vistas31 diapositivas

Último(20)

The Art of naming drugs.pptx por DanaKarem1
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptx
DanaKarem113 vistas
Examining Pleural Fluid.pptx por Fareeha Riaz
Examining Pleural Fluid.pptxExamining Pleural Fluid.pptx
Examining Pleural Fluid.pptx
Fareeha Riaz 19 vistas
3rd lecture PCR-Presentation.ppt por gayubshah
3rd lecture PCR-Presentation.ppt3rd lecture PCR-Presentation.ppt
3rd lecture PCR-Presentation.ppt
gayubshah6 vistas
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f... por PeerVoice
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
PeerVoice6 vistas
Depression PPT template por EmanMegahed6
Depression PPT templateDepression PPT template
Depression PPT template
EmanMegahed622 vistas
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler) por The Swiss Pharmacy
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler) Asthalin Inhaler (Generic Albuterol Sulfate Inhaler)
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler)
The Swiss Pharmacy10 vistas
eTEP -RS Dr.TVR.pptx por Varunraju9
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptx
Varunraju9142 vistas
Peptic ulcer.pdf por UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS12 vistas
FAT ATER SOND WALUBLE VITAMINS por BeshedaWedajo
FAT ATER SOND WALUBLE VITAMINS  FAT ATER SOND WALUBLE VITAMINS
FAT ATER SOND WALUBLE VITAMINS
BeshedaWedajo7 vistas
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx por JubinNath2
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxCMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
JubinNath28 vistas
Pulmonary Embolism for Nurses.pptx por Asraf Hussain
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptx
Asraf Hussain33 vistas
Drug induced hepatitis.pptx por ImanShafqat
Drug induced hepatitis.pptxDrug induced hepatitis.pptx
Drug induced hepatitis.pptx
ImanShafqat8 vistas
DEBATE IN CA BLADDER TMT VS CYSTECTOMY por Kanhu Charan
DEBATE IN CA BLADDER TMT VS CYSTECTOMYDEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
Kanhu Charan50 vistas
Structural Racism and Public Health: How to Talk to Policymakers and Communit... por katiequigley33
Structural Racism and Public Health: How to Talk to Policymakers and Communit...Structural Racism and Public Health: How to Talk to Policymakers and Communit...
Structural Racism and Public Health: How to Talk to Policymakers and Communit...
katiequigley331.1K vistas

Stronger Life Science Patents (MichBio)

  • 1. Stronger Life Science Patents This presentation is for information purposes only and does not constitute legal advice. ASHLEY SLOAT, Ph.D. | September 18, 2023
  • 2. Ashley Sloat, Ph.D. President & Director of Patent Strategy
  • 3. an illogical, unpredictable, chaotic mess... “ – Federal Circuit Chief Judge Paul Michel (retired)
  • 4. made it difficult for inventors, businesses, and other patent stakeholders to reliably and predictably determine what subject matter is patent eligible “ – Elizabeth Prelogar, U.S. Solicitor General
  • 5. innovation cannot thrive in uncertainty “ – Kathi Vidal, USPTO Director and Under Secretary of Commerce
  • 6. 80% innovation does not include patentable subject matter
  • 8. Let us be clear: investments in the biotech industry are based entirely on patents. Without strong patents, we cannot raise money to find cures for disease. “ – Hans Bishop, Founder at Altos Labs & former Head of Juno Therapeutics
  • 10. Overview: Stronger Life Science Patents •Eligibility and enablement •State of the law •Funding sources and regulatory delays •Practical tips •Recent legislative movements
  • 11. There are seven days in the week and SOMEDAY isn’t one of them. “
  • 12. Rejection & Invalidation Gates • Section 101 – patent ineligibility or lack of utility • Section 102 – lack of novelty • Section 103 – the claimed invention is obvious and/or • Section 112 – lack of adequate description
  • 13. Eligibility. What subject matters are eligible for patent protection?
  • 14. Enablement. The fundamental deal of the patent system.
  • 15. Eligibility: Patentable Subject Matter “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” 35 U.S.C. § 101
  • 16. Eligibility: Judicial Exceptions • Laws of nature • Natural phenomena • Abstract ideas
  • 17. Eligibility: Judicial Exceptions • scientific principles • naturally occurring phenomena • mental processes • mathematical algorithms
  • 18. Practical application of natural phenomenon Life Science Challenge:
  • 19. The Reality of Past 5 Years 1631 Art Unit Molecular Bio, Bioinformatics, Nucleic Acids, Recombinant DNA/RNA, Gene Regulation
  • 20. Mayo Collaborative Services v. Prometheus Laboratories, Inc. Unpatentable natural laws transformed into patent-eligible applications of those laws?
  • 21. Statutory Category? YES Judicial Exception? Practical Application? YES Significantly More? NO YES NO YES Eligible NO Subject Matter Eligibility Guidance Process machine manufacture composition of matter Laws of nature Natural phenomena Abstract ideas Not Eligible NO
  • 22. Ariosa Diagnostics, Inc. v. Sequenom, Inc. A significant, but unpatentable, contribution to the medical field.
  • 23. The solution lies in the intent “…in applying the §101 exception, we must distinguish between patents that claim the building blocks of human ingenuity and those that integrate the building blocks into something more, thereby transforming them into a patent-eligible invention” Alice Corp. v. CLS Bank Int’l SCOTUS opinion
  • 24. The solution lies in the intent “At some level, all inventions embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas. Thus, an invention is not rendered ineligible for patent simply because it involves an abstract concept. Applications of such concepts to a new and useful end … remain eligible for patent protection.” Alice Corp. v. CLS Bank Int’l SCOTUS opinion
  • 25. Key Tips for Derisking Eligibility • Practical applications. • Improvement over prior art methods. • Overcome a particular technical challenge. • Different claim types. Building blocks into something more
  • 26. "Unless you puke, faint or die, keep going!" – Jillian Michaels
  • 27. Enablement. The fundamental deal of the patent system.
  • 28. Enablement: Adequate Description “The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art … to make and use the same…” 35 U.S.C. § 112
  • 29. Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them 101 Patentable Subject Matter 102 Novelty 103 Obviousness 112a Written Description 112b Enablement All Rejection Bases
  • 30. Top Art Unit Groups for 112 Rejections Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
  • 31. Higher disclosure bar for unpredictable arts Life Science Challenge:
  • 32. Enabling Unpredictable Arts “the scope of enablement … varies inversely with the degree of unpredictability of the factors involved” Application of Joseph D. Fisher, 427 F.2d 833 (C.C.P.A. 1970) Enablement Mechanical arts Physics Chemical arts Life Sciences Predictability Digital Health
  • 33. The Enablement Test “…as to enable any person skilled in the art … to make and use the … invention.” 35 U.S.C. § 112 “…without undue experimentation”. Minerals Separation Ltd. v. Hyde ... coupled with information known in the art ...”. United States v. Telectronics, Inc
  • 34. Genus Claim: covers a group of related chemicals Species Claim: covers a single compound or narrow slice of compounds possibly without coverage of analogs, derivatives, or compounds in the same family
  • 35. …the law has changed dramatically in the last thirty years, to the point where it is nearly impossible to maintain a valid genus claim. Courts almost always hold them invalid, either at trial or on appeal. “ Harvard Journal of Law & Technology: Death of the Genus Claim
  • 36. USPTO Genus Misinformation Disputed by Third Parties Community reports have identified this guidance as violating the Community Policy on Harmfully Misleading Information United States Patent and Trademark Office MPEP III. WORKING EXAMPLES AND A CLAIMED GENUS For a claimed genus, representative examples together with a statement applicable to the genus as a whole will ordinarily be sufficient if one skilled in the art …would expect the claimed genus could be used in that manner without undue experimentation. Proof of enablement will be required for other members of the claimed genus only where adequate reasons are advanced by the examiner to establish that a person skilled in the art could not use the genus as a whole without undue experimentation.
  • 37. Examples of the Genus Claim Deaths • A nascent, unpredictable field rife with failure can cause enablement issues –Enzo Biochem v. Calgene (Fed. Circ. 1999) –Claimed antisense DNA technology • Iterative trial-and-error lead by spec can create enablement issue –Wyeth v. Abbott (Fed. Circ. 2010) –Rapamycin chemicals for treatment of restenosis
  • 38. Death of the Genus Claim • Undue Experimentation despite described screening process allowing for straightforward ID of working embodiments – Idenix Pharma v. Gilead (Fed. Circ. 2019) – 2-methyl nucleoside for treatment of HCV • Not Enabled despite antibody science being well- known, guidance provided, working examples, identified specific amino acids for binding – Amgen v. Sanofi (Supreme Court 2023)
  • 39. The solution lies in the intent A bargain between the inventor and society.
  • 40. Wands Factors 1. Quantity of experimentation necessary 2. Amount of direction or guidance presented 3. Presence or absence of working examples 4. Nature of the invention 5. State of the prior art 6. Relative skill of those in the art 7. Predictability or unpredictability of the art 8. Breadth of the claims In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
  • 41. Key Tips for Derisking Enablement • Provide ample direction and specificity. • Build breadth through examples. • Reinforce genus with species. • Consider a narrower claim backstop. • Disclose experimentation tips. • File continuation applications. • Consider alternative strategies.
  • 42. Funding Sources and Regulatory Delays Life Science Challenges:
  • 44. Government Grant Gotchyas 1. Actually reduce invention to practice before using money – otherwise Gov’t has a nonexclusive, nontransferrable, irrevocable, paid-up license to practice the invention throughout the world • Even if your patent was filed before the grant…. 2. If subject invention is unelected at 2 years, then gov’t receives title of invention. 3. If hire subcontractor to perform some of the work, any subject invention from the subcontractor cannot be assigned to your company – subcontractor retains ownership.
  • 46. Maximize Your Exclusivity Window 1. Patent Term Extension 2. New Drug Product Exclusivity 3. New Clinical Investigation Exclusivity
  • 47. “trainers who say ‘last one’ are the reason I have trust issues"
  • 48. Reform on the horizon? Current events and legislative solutions.
  • 49. Patent Eligibility Restoration Act of 2023 • Would amend the U.S. Patent Act to clarify the application of 35 U.S.C. Section 101 and address uncertainty plaguing software and biotechnology inventions • Effectively overruling Alice and previous SCOTUS cases such as Mayo • Wide bipartisan and community support
  • 51. Stronger Life Science Patent Resources • This slide deck • Blog posts on timelines and exclusivity • Podcasts on enablement and gov’t grants
  • 52. Questions or Comments? Contact us! ashley@aurorapatents.com (231) 715-1001 aurorapatents.com @AuroraPatents Podcast @ patentlystrategic.buzzsprout.com